Boosting NAD+ with a small molecule that activates NAMPT

Stephen J. Gardell, Meghan Hopf, Asima Khan, Mauro Dispagna, E. Hampton Sessions, Rebecca Falter, Nidhi Kapoor, Jeanne Brooks, Jeffrey Culver, Chris Petucci, Chen Ting Ma, Steven E. Cohen, Jun Tanaka, Emmanuel S. Burgos, Jennifer S. Hirschi, Steven R. Smith, Eduard Sergienko, Anthony B. Pinkerton

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pharmacological strategies that boost intracellular NAD+ are highly coveted for their therapeutic potential. One approach is activation of nicotinamide phosphoribosyltransferase (NAMPT) to increase production of nicotinamide mononucleotide (NMN), the predominant NAD+ precursor in mammalian cells. A high-throughput screen for NAMPT activators and hit-to-lead campaign yielded SBI-797812, a compound that is structurally similar to active-site directed NAMPT inhibitors and blocks binding of these inhibitors to NAMPT. SBI-797812 shifts the NAMPT reaction equilibrium towards NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT at His247, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD+. These effects of SBI-797812 turn NAMPT into a “super catalyst” that more efficiently generates NMN. Treatment of cultured cells with SBI-797812 increases intracellular NMN and NAD+. Dosing of mice with SBI-797812 elevates liver NAD+. Small molecule NAMPT activators such as SBI-797812 are a pioneering approach to raise intracellular NAD+ and realize its associated salutary effects.

Original languageEnglish (US)
Article number3241
JournalNature Communications
Volume10
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Nicotinamide Phosphoribosyltransferase
nicotinamide
NAD
Nicotinamide Mononucleotide
Molecules
molecules
Cells
inhibitors
Liver
Byproducts
Cultured Cells
Catalytic Domain
adenosine triphosphate
Adenosine Triphosphate
Chemical activation
Throughput
Pharmacology
acceleration (physics)
cultured cells
liver

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Gardell, S. J., Hopf, M., Khan, A., Dispagna, M., Hampton Sessions, E., Falter, R., ... Pinkerton, A. B. (2019). Boosting NAD+ with a small molecule that activates NAMPT. Nature Communications, 10(1), [3241]. https://doi.org/10.1038/s41467-019-11078-z

Boosting NAD+ with a small molecule that activates NAMPT. / Gardell, Stephen J.; Hopf, Meghan; Khan, Asima; Dispagna, Mauro; Hampton Sessions, E.; Falter, Rebecca; Kapoor, Nidhi; Brooks, Jeanne; Culver, Jeffrey; Petucci, Chris; Ma, Chen Ting; Cohen, Steven E.; Tanaka, Jun; Burgos, Emmanuel S.; Hirschi, Jennifer S.; Smith, Steven R.; Sergienko, Eduard; Pinkerton, Anthony B.

In: Nature Communications, Vol. 10, No. 1, 3241, 01.12.2019.

Research output: Contribution to journalArticle

Gardell, SJ, Hopf, M, Khan, A, Dispagna, M, Hampton Sessions, E, Falter, R, Kapoor, N, Brooks, J, Culver, J, Petucci, C, Ma, CT, Cohen, SE, Tanaka, J, Burgos, ES, Hirschi, JS, Smith, SR, Sergienko, E & Pinkerton, AB 2019, 'Boosting NAD+ with a small molecule that activates NAMPT', Nature Communications, vol. 10, no. 1, 3241. https://doi.org/10.1038/s41467-019-11078-z
Gardell SJ, Hopf M, Khan A, Dispagna M, Hampton Sessions E, Falter R et al. Boosting NAD+ with a small molecule that activates NAMPT. Nature Communications. 2019 Dec 1;10(1). 3241. https://doi.org/10.1038/s41467-019-11078-z
Gardell, Stephen J. ; Hopf, Meghan ; Khan, Asima ; Dispagna, Mauro ; Hampton Sessions, E. ; Falter, Rebecca ; Kapoor, Nidhi ; Brooks, Jeanne ; Culver, Jeffrey ; Petucci, Chris ; Ma, Chen Ting ; Cohen, Steven E. ; Tanaka, Jun ; Burgos, Emmanuel S. ; Hirschi, Jennifer S. ; Smith, Steven R. ; Sergienko, Eduard ; Pinkerton, Anthony B. / Boosting NAD+ with a small molecule that activates NAMPT. In: Nature Communications. 2019 ; Vol. 10, No. 1.
@article{1c0db071d7674a089d8b58c8a84b653e,
title = "Boosting NAD+ with a small molecule that activates NAMPT",
abstract = "Pharmacological strategies that boost intracellular NAD+ are highly coveted for their therapeutic potential. One approach is activation of nicotinamide phosphoribosyltransferase (NAMPT) to increase production of nicotinamide mononucleotide (NMN), the predominant NAD+ precursor in mammalian cells. A high-throughput screen for NAMPT activators and hit-to-lead campaign yielded SBI-797812, a compound that is structurally similar to active-site directed NAMPT inhibitors and blocks binding of these inhibitors to NAMPT. SBI-797812 shifts the NAMPT reaction equilibrium towards NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT at His247, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD+. These effects of SBI-797812 turn NAMPT into a “super catalyst” that more efficiently generates NMN. Treatment of cultured cells with SBI-797812 increases intracellular NMN and NAD+. Dosing of mice with SBI-797812 elevates liver NAD+. Small molecule NAMPT activators such as SBI-797812 are a pioneering approach to raise intracellular NAD+ and realize its associated salutary effects.",
author = "Gardell, {Stephen J.} and Meghan Hopf and Asima Khan and Mauro Dispagna and {Hampton Sessions}, E. and Rebecca Falter and Nidhi Kapoor and Jeanne Brooks and Jeffrey Culver and Chris Petucci and Ma, {Chen Ting} and Cohen, {Steven E.} and Jun Tanaka and Burgos, {Emmanuel S.} and Hirschi, {Jennifer S.} and Smith, {Steven R.} and Eduard Sergienko and Pinkerton, {Anthony B.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41467-019-11078-z",
language = "English (US)",
volume = "10",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Boosting NAD+ with a small molecule that activates NAMPT

AU - Gardell, Stephen J.

AU - Hopf, Meghan

AU - Khan, Asima

AU - Dispagna, Mauro

AU - Hampton Sessions, E.

AU - Falter, Rebecca

AU - Kapoor, Nidhi

AU - Brooks, Jeanne

AU - Culver, Jeffrey

AU - Petucci, Chris

AU - Ma, Chen Ting

AU - Cohen, Steven E.

AU - Tanaka, Jun

AU - Burgos, Emmanuel S.

AU - Hirschi, Jennifer S.

AU - Smith, Steven R.

AU - Sergienko, Eduard

AU - Pinkerton, Anthony B.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Pharmacological strategies that boost intracellular NAD+ are highly coveted for their therapeutic potential. One approach is activation of nicotinamide phosphoribosyltransferase (NAMPT) to increase production of nicotinamide mononucleotide (NMN), the predominant NAD+ precursor in mammalian cells. A high-throughput screen for NAMPT activators and hit-to-lead campaign yielded SBI-797812, a compound that is structurally similar to active-site directed NAMPT inhibitors and blocks binding of these inhibitors to NAMPT. SBI-797812 shifts the NAMPT reaction equilibrium towards NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT at His247, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD+. These effects of SBI-797812 turn NAMPT into a “super catalyst” that more efficiently generates NMN. Treatment of cultured cells with SBI-797812 increases intracellular NMN and NAD+. Dosing of mice with SBI-797812 elevates liver NAD+. Small molecule NAMPT activators such as SBI-797812 are a pioneering approach to raise intracellular NAD+ and realize its associated salutary effects.

AB - Pharmacological strategies that boost intracellular NAD+ are highly coveted for their therapeutic potential. One approach is activation of nicotinamide phosphoribosyltransferase (NAMPT) to increase production of nicotinamide mononucleotide (NMN), the predominant NAD+ precursor in mammalian cells. A high-throughput screen for NAMPT activators and hit-to-lead campaign yielded SBI-797812, a compound that is structurally similar to active-site directed NAMPT inhibitors and blocks binding of these inhibitors to NAMPT. SBI-797812 shifts the NAMPT reaction equilibrium towards NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT at His247, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD+. These effects of SBI-797812 turn NAMPT into a “super catalyst” that more efficiently generates NMN. Treatment of cultured cells with SBI-797812 increases intracellular NMN and NAD+. Dosing of mice with SBI-797812 elevates liver NAD+. Small molecule NAMPT activators such as SBI-797812 are a pioneering approach to raise intracellular NAD+ and realize its associated salutary effects.

UR - http://www.scopus.com/inward/record.url?scp=85069435068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069435068&partnerID=8YFLogxK

U2 - 10.1038/s41467-019-11078-z

DO - 10.1038/s41467-019-11078-z

M3 - Article

C2 - 31324777

AN - SCOPUS:85069435068

VL - 10

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 3241

ER -